<DOC>
	<DOCNO>NCT00220402</DOCNO>
	<brief_summary>This trial provide long-term data safety , satisfaction maintenance therapy fesoterodine ( SPM 907 ) subject overactive bladder syndrome . Subjects complete 12 week treatment period SP583 opportunity participate eligibility confirm . They receive fesoterodine 8mg option reduce dose 4mg scheduled visit , increase 8mg , procedure could follow annual basis . Two primary efficacy variable assess , observation assessment adverse event duration therapy . Secondary efficacy parameter include various parameter derive micturition diary evaluation Quality Life questionnaire ( KHQ ICIQ-SF ) . The important safety variable include assessment adverse event , laboratory parameter , change ECG , physical exam measurement residual urine .</brief_summary>
	<brief_title>Long-Term Open-Label Extension Trial Subjects Completing Phase 3 Trial Fesoterodine ( SP583 ) Treatment Overactive Bladder Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Participated SP583 Failure complete 12 week treatment SPM 907</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>